143 related articles for article (PubMed ID: 26924735)
1. Survivin Modulators: An Updated Patent Review (2011-2015).
Roy K; Singh N; Kanwar RK; Kanwar JR
Recent Pat Anticancer Drug Discov; 2016; 11(2):152-69. PubMed ID: 26924735
[TBL] [Abstract][Full Text] [Related]
2. Treat cancers by targeting survivin: just a dream or future reality?
Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
[TBL] [Abstract][Full Text] [Related]
3. Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.
Santarelli A; Mascitti M; Lo Russo L; Sartini D; Troiano G; Emanuelli M; Lo Muzio L
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587347
[TBL] [Abstract][Full Text] [Related]
4. Survivin in solid tumors: rationale for development of inhibitors.
Church DN; Talbot DC
Curr Oncol Rep; 2012 Apr; 14(2):120-8. PubMed ID: 22234703
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine.
Ghanbari P; Mohseni M; Tabasinezhad M; Yousefi B; Saei AA; Sharifi S; Rashidi MR; Samadi N
Appl Biochem Biotechnol; 2014 Sep; 174(2):667-81. PubMed ID: 25086926
[TBL] [Abstract][Full Text] [Related]
6. Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
Rödel F; Sprenger T; Kaina B; Liersch T; Rödel C; Fulda S; Hehlgans S
Curr Med Chem; 2012; 19(22):3679-88. PubMed ID: 22680927
[TBL] [Abstract][Full Text] [Related]
7. Targeting survivin in cancer: the cell-signalling perspective.
Kanwar JR; Kamalapuram SK; Kanwar RK
Drug Discov Today; 2011 Jun; 16(11-12):485-94. PubMed ID: 21511051
[TBL] [Abstract][Full Text] [Related]
8. The role of survivin for radiation oncology: moving beyond apoptosis inhibition.
Rödel F; Reichert S; Sprenger T; Gaipl US; Mirsch J; Liersch T; Fulda S; Rödel C
Curr Med Chem; 2011; 18(2):191-9. PubMed ID: 21110807
[TBL] [Abstract][Full Text] [Related]
9. Targeting survivin for therapeutic discovery: past, present, and future promises.
Peery RC; Liu JY; Zhang JT
Drug Discov Today; 2017 Oct; 22(10):1466-1477. PubMed ID: 28577912
[TBL] [Abstract][Full Text] [Related]
10. Survivin as a Potential Target for Cancer Therapy.
Soleimanpour E; Babaei E
Asian Pac J Cancer Prev; 2015; 16(15):6187-91. PubMed ID: 26434815
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology based platforms for survivin targeted drug discovery.
Samarasinghe RM; Gibbons J; Kanwar RK; Kanwar JR
Expert Opin Drug Discov; 2012 Nov; 7(11):1083-92. PubMed ID: 22950742
[TBL] [Abstract][Full Text] [Related]
12. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
[TBL] [Abstract][Full Text] [Related]
13. Survivin as a preferential target for cancer therapy.
Mobahat M; Narendran A; Riabowol K
Int J Mol Sci; 2014 Feb; 15(2):2494-516. PubMed ID: 24531137
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy.
Wang S; Xu Y; Chan HF; Kim HW; Wang Y; Leong KW; Chen M
J Control Release; 2016 Oct; 240():454-464. PubMed ID: 27091696
[TBL] [Abstract][Full Text] [Related]
15. The role of survivin in the diagnosis and therapy of gynaecological cancers.
Denel-Bobrowska M; Marczak A
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1182-1189. PubMed ID: 28026821
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
17. [Survivin antisense RNA induces apoptosis and sensitizes ovarian cancer cell line SKOV3 to docetaxel].
Ma R; Chen XH; Tang LP; Geng XX; Sui LH; Zhang YL
Ai Zheng; 2006 Apr; 25(4):393-7. PubMed ID: 16613668
[TBL] [Abstract][Full Text] [Related]
18. [Exploration on the increased sensitivity to docetaxel and reversing mechanism of drug resistance of antisense survivin RNA in gastric cancer cell line SGC7901 cells].
Ma R; Chen XH; Zhang QF; Zhu L; Tang LP; Wang J; Cheng HY; Lei LN
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):89-92. PubMed ID: 17645838
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
